Schrodinger Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Schrodinger Inc in the market are companies like OpenEye Scientific Software, BioSolveIT, and Chemical Computing Group.

Schrodinger Inc is a renowned chemical simulation and computational drug discovery company. Established in 1990, it has been a pioneer in utilizing physics-based algorithms to accelerate the discovery and development of novel drugs. With a strong focus on research and technology innovation, Schrodinger Inc has emerged as a leader in the field, providing cutting-edge solutions to leading pharmaceutical and biotechnology companies worldwide. By leveraging advanced computational techniques, including molecular dynamics simulations and quantum mechanics, the company enables scientists to gain valuable insights into drug-target interactions, leading to the identification of potential therapeutics. Schrodinger Inc's rich history and expertise make it a trusted partner in accelerating the drug discovery process.

Schrodinger Inc, a renowned company specializing in computational drug discovery, has achieved significant milestones since its inception. The company has developed innovative software solutions and platforms, including the widely acclaimed Schrodinger Suite, which revolutionizes drug discovery processes. Schrodinger Inc has collaborated with prominent pharmaceutical companies, accelerated drug discovery initiatives, and contributed to the development of breakthrough therapies. With its cutting-edge technologies and expertise, the company has successfully advanced multiple drug discovery programs, addressing critical diseases and meeting the evolving needs of the pharmaceutical industry. Schrodinger Inc continues to pave the way in computational chemistry, providing valuable solutions for drug designers and researchers worldwide.

Schrodinger Inc is primarily present worldwide, with a strong presence in North America, Europe, and Asia. The company's global reach allows it to serve customers and collaborate with partners across borders. Schrodinger Inc's diverse international presence helps foster innovation and the development of cutting-edge computational tools for drug discovery and materials science.

Schrodinger Inc represents a set of core values and a strong corporate philosophy. The company focuses on delivering innovative solutions in the field of computational chemistry and advancing drug discovery and materials science. Schrodinger Inc believes in a multidisciplinary approach, combining scientific expertise with cutting-edge technology to empower researchers and accelerate scientific breakthroughs. With a commitment to collaboration, integrity, and excellence, Schrodinger Inc aims to transform the way pharmaceutical and biotechnology industries approach research and development. By harnessing the power of physics-based simulations and computational models, Schrodinger Inc strives to revolutionize drug discovery and contribute to the advancement of human health.

Analysts currently set an average price target of 25.95 USD for the Schrodinger stock (median: 25.50 USD), implying +60.2 % versus the latest price. The consensus is based on 16 analyst ratings.

Schrodinger Analyst Price Targets 2026

15 analysts currently rate the Schrodinger stock: 12 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Schrodinger to generate revenue of 234.72 M USD and earnings per share of -2.00 USD.

Schrodinger Analyst Price Targets 2026

Converted at the current exchange rate, the Schrodinger share trades at 14.02 EUR (16.20 USD).

The Schrodinger share (SDGR) is listed on 4 stock exchanges, including: NASDAQ (SDGR), Frankfurt (43Z.F), München (43Z.MU), Düsseldorf (43Z.DU).

Schrodinger Inc. is a biomedical company based in the United States that specializes in using computer simulations for the development of drugs and chemicals. The company was founded in 1990 by Dr. William L. Jorgensen and is headquartered in New York City. Schrodinger Inc.'s business model is based on the development of simulation software used to accelerate the drug development process, as well as the development of pesticides and other chemicals. The company offers software and services in the fields of medicinal chemistry, materials science, biology, and toxicology. Some of its software products include the Schrödinger Suite, a leading package for molecular simulations and modeling. In addition, the company offers a cloud-based platform called LiveDesign, which allows customers to collaborate with the Schrodinger team securely. Through this platform, users can access data and models in real-time to make faster decisions and achieve multiple goals in shorter timeframes. In the field of drug development, Schrodinger Inc. also offers compute-based services. The company provides its customers with a data-driven approach to identify drug candidates and optimize their pharmacological properties, allowing for faster identification of active ingredients and saving time and money. Additionally, Schrodinger Inc. is capable of delivering its software and services as cloud-based platforms to customers in the biotechnology industry who have limited IT resources. Customers can utilize a private cloud to host their own data and applications, gaining access to a scalable and flexible infrastructure that can quickly and efficiently respond to industry demands. With its innovative and effective technology supporting drug development, Schrodinger Inc. has established itself as a trusted provider of computer-based solutions in the pharmaceutical and biotechnology industries. With a strong focus on research and development, the company remains at the forefront of the industry and is well-positioned to continue growing and expanding.

The expected revenue of Schrodinger is 234.72 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Schrodinger is -147.23 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Schrodinger is currently -8.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Schrodinger stock.

The price-to-sales ratio (P/S) of Schrodinger is currently 5.07. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Schrodinger stock.

The Eulerpool Quality Score for Schrodinger is 3/10.

The ISIN of Schrodinger is US80810D1037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Schrodinger is A2PY7M. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Schrodinger is SDGR. The ticker symbol is used to trade Schrodinger shares on the stock exchange.

Schrodinger paid dividends every year for the past 0 years.

Schrodinger is assigned to the 'Health' sector.

The dividends of Schrodinger are distributed in USD.